Home Newsfeeds Needham Initiates Coverage On Duolingo with Buy Rating, Announces Price Target of $115

Needham Initiates Coverage On Duolingo with Buy Rating, Announces Price Target of $115

Needham analyst Ryan MacDonald initiates coverage on Duolingo (NASDAQ:DUOL) with a Buy rating and announces Price Target of $115.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Needham analyst Ryan MacDonald initiates coverage on Duolingo (NASDAQ:DUOL) with a Buy rating and announces Price Target of $115.

News
Tech

You Might Get A Dedicated Button To Click Photos On The iPhone 16

By Rounak Jain

November 1, 5:30 AM

A new leak has once again suggested that Apple's iPhone 16 may feature a capacitive button that will work as a dedicated capture button.

AAPL

Price Over Earnings Overview: Banco Santander

By Benzinga Insights

November 7, 3:15 PM

Looking into the current session, Banco Santander Inc. (NYSE:SAN) shares are trading at $3.72, after a 1.33% drop.…

SAN

Cramer Tells Investors To Focus On Great Businesses That Seized Control Of Their Destinies: ‘Nobody Does That Better Than Apple’

By Bhavik Nair

May 24, 6:29 AM

Prominent market commentator Jim Cramer has reportedly advised investors to focus on those companies that have customer service…

AAPL

Processa Pharmaceuticals Provides Interim Analysis From Ongoing Phase 1b Trial Of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

By Benzinga Newsdesk

December 19, 10:05 AM

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FUInterim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU

PCSA

Needham Initiates Coverage On Duolingo with Buy Rating, Announces Price Target of $115

Related Posts

You Might Get A Dedicated Button To Click Photos On The iPhone 16

Price Over Earnings Overview: Banco Santander

Cramer Tells Investors To Focus On Great Businesses That Seized Control Of Their Destinies: ‘Nobody Does That Better Than Apple’

Processa Pharmaceuticals Provides Interim Analysis From Ongoing Phase 1b Trial Of Next Generation Capecitabine Showing Improved Safety Over Capecitabine